摘要
目的探讨乳腺癌中多药耐药基因MDR1/P-gp与CerbB-2、p53表达的关系及临床意义。方法采用免疫组化SP法,检测186例手术切除的乳腺癌组织中P-gp与CerbB-2、p53蛋白的表达。结果乳腺癌组织中P-gp与CerbB-2、p53蛋白的阳性表达率分别为41.4%、51.1%、38.7%。P-gp蛋白阳性组CerbB-2过表达率高于P-gp蛋白阴性组,过表达率分别为37.66%、20.18%,差异有显著性意义(P<0.01)。P-gp蛋白阳性组p53过表达率也高于P-gp蛋白阴性组,过表达率分别为28.57%、15.60%,差异有显著性(P<0.05)。P-gp表达与患者原发肿瘤的大小、淋巴结转移状况、TNM分期、病理类型以及E、P激素受体状况无关(P>0.05)。CerbB-2、p53表达在淋巴结转移的乳腺癌患者中明显升高。结论乳腺癌中存在MDR1/P-gp与CerbB-2、P53基因共表达,与多药耐药有关。联合检测可为乳腺癌患者综合治疗方案的选择提供重要的依据。
Objective To investigate the correlation between expression of MDRI/P - gp gene and CerbB - 2, p53 genes and its clinical significance in breast cancer. Methods SP immunohistochemical method was used to detect the expression of MDRI/P- gp gene and CerbB - 2, p53 genes in breast cancer. Results The positive rates of expression of MDRI/P - gp, CerbB - 2, and p53 were 41.4 %, 51.1% and 38. ？ %, respectively. The overexpression rate of CerbB - 2 was significantly higher in the group with expression of P- gp （37.66 % ） than that in the group with non- expression of P- gp （20.18 % ）. The overexpression rate of p53 was also higher in the group with expression of P- gp （28.57 % ） than that in the group with non- expression of P- gp （15.60%）. The expression of P- gp was not correlated with tumor diameter, lymph node metastasis, clinical stages, pathological types and the receptors for estrogen and progestogen （P〉 0.0.5）. The positive rate of CerbB- 2 and p53 expression was significantly increased in axillary lymph node positive breast cancer. Conclusions MDRI/P - gp, CerbB- 2 and p53 are co - expressed in breast cancer and have a relationship with multidrug resistance. Combined detection might be useful in the establishment of synthetic therapy regimen in breast cancer.
出处
《实用预防医学》
CAS
2007年第6期1702-1704,共3页
Practical Preventive Medicine
